International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.
International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.
Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.
Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.
Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.
Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.
Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.
International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.
Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.
Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.
Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.
An International Open Access Journal Devoted to General Medicine.
Castleman disease is a relatively rare non-clonal lymphoproliferative disease characterized by the histopathological findings of the lymph nodes, as reported by Castleman et al (1). Clinically, it is classified into unicentric Castleman disease (UCD), in which the affected lymph nodes are confined to a single region, and multicentric Castleman disease (MCD), characterized by generalized lymphadenopathy (2–5). The clinical symptoms of CD include a variety of systemic symptoms and abnormalities upon testing. CD is characterized by histological findings such as lymphoid follicle hyperplasia and vascular invasion into lymphoid follicles, and is definitively diagnosed based on histopathological findings. The most common site of Castleman disease is the mediastinum, accounting for approximately 70% of all cases; however, 15% of such cases occur in the head and neck (6). Therefore, it is necessary to keep in mind the concept of Castleman disease when cervical lymphadenopathy is observed. However, it is extremely rare for Castleman disease to occur in association with head and neck cancer cases, including oral cancer, in which case it becomes difficult to distinguish between the metastatic lymph nodes from head and neck cancer and Castleman disease. Furthermore, the treatment for the two diseases is completely different, so proper diagnosis is essential.
We experienced a case of MCD that was incidentally detected during an evaluation of tongue cancer, and report this case with a review of the pertinent literature.
A 73-year-old male was referred to our department by our Internal Medicine Department in May 2022 under a suspicion of tongue cancer on the left side. The patient became aware of pain in the same region one month prior to his initial visit. His medical history included chronic kidney disease, hypothyroidism, chronic stasis dermatitis, and anemia. At his initial visit, a 25×15 mm exophytic tumor with a slightly ambiguous border was observed on the left side of his tongue; however, no paresthesia of the lingual nerve was observed (Fig. 1). In addition, no obvious swelling or tenderness of the cervical lymph nodes was palpable. A biopsy revealed well-differentiated squamous cell carcinoma (Fig. 2). A neoplastic lesion measuring 25×15×4 mm in size was observed on the left side of his tongue upon Computed tomography (CT) and Magnetic resonance imaging (MRI), with mild enlargement observed in the submental lymph nodes and left submandibular lymph nodes; however, no lung lesions were observed (Fig. 3). F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) revealed a strong accumulation of SUVmax 6.9 on the left side of his tongue. An abnormal FDG uptake was also observed in the submental lymph node (SUVmax 5.2) and the left submandibular lymph node (SUVmax 4.8) (Fig. 4). In addition, multiple intense accumulations (SUVmax 1.7–6.5) were detected in the lymph nodes of both axillae, around the abdominal aorta, in the pelvic cavity, and in both inguinal regions (Fig. 5). Blood test results indicated low values of hemoglobin content (Hb) at 10.4 g/dl and albumin (Alb) at 3 1g/dl, a slightly elevated C-reactive protein (CRP) at 1.79 mg/dl, and a high γ-globulin fraction in the protein fractionation pattern at 38.4%. Although lymphoproliferative disorder was suspected, metastasis from tongue cancer to the cervical lymph nodes could not be ruled out. For this reason, we performed fine needle aspiration (FNA) on the submental lymph nodes and left submandibular lymph nodes, while observing no atypical epithelial cells suggesting metastasis (Fig. 6). In addition, we consulted our Dermatology Department and performed a lymph node biopsy from the left inguinal region. Histologically, we observed follicle formation with an embryonic center and significant plasma cell proliferation around the follicle. When we investigated kappa/lambda chains by means of clonality studies, the plasma cells were not biased by kappa/lambda chains and immunohistochemistry did not reveal any findings that could be considered to be tumor proliferation. Since there was also no amyloid deposition, the patient was diagnosed with a plasma cell variant of Castleman disease (Fig. 7).
Based on the above, in August 2022, a left partial glossectomy was performed under general anesthesia with a diagnosis of left lingual squamous cell carcinoma (cT2N0M0, stage II) along with MCD. Following the resection, the wound was sutured with 4-0 absorbent sutures (Fig. 8). Histopathologically, the lesion showed a sheet-like proliferation of atypical squamous cells with a tendency to keratinize, thus forming large and small nests and infiltrating into the superficial muscle layer. Moreover, low-grade dysplasia was observed in the white mucosa around the tumor (Fig. 9). The depth of invasion was 2 mm and venous infiltration was observed; however, no lymphatic vessels or nerve infiltration was observed. Based on the above, the lesion was diagnosed as squamous cell carcinoma (SCC) of the tongue (pT2N0M0, grade 1, stage II). Our hematology department thereafter was responsible for the treatment for Castleman disease. Because the symptoms were mild and asymptomatic, with the 10-year survival rate expected to be 80% even without treatment, our course of action was to monitor his progress without using any immunosuppressive drugs and tocilizumab. It was decided that if symptoms such as fatigue and slight fever appeared, then the administration of 0.3 mg/kg/day of prednisolone will be initiated, and if these symptoms were to either worsen or if organ symptoms are observed, then the administration of tocilizumab would be considered while increasing the dose of prednisolone to 1 mg/kg/day. Postoperatively, the patient has been undergoing monthly follow-up visits and CT scans every three months to monitor the status of his tongue and the lymph node lesions. Currently, there has been no evidence of any recurrent metastasis of the tongue cancer even 30 months following surgery, and with no progression of Castleman disease observed.
Castleman disease is a non-neoplastic lymphoproliferative disorder of unknown origin and it is a relatively rare disease that was reported by Castleman et al (1) in 1956. Subsequently, it was histopathologically classified into three types by Keller et al (7): hyaline vascular type (HV type); plasma cell type (PC type); and mixed type (M type). HV type is histologically characterized by the proliferation of lymphoid follicles and the proliferation and vitrification of blood vessels between follicles. It has few clinical symptoms and it rarely demonstrates abnormal values upon blood testing. On the other hand, PC type is characterized by the diffuse, sheet-like infiltration of plasma cells into the interfollicular tissue and expansion of the follicular spaces, which often causes a variety of clinical symptoms such as generalized lymphadenopathy, anemia, and abnormal blood tests. Although there are no specific immunohistochemical markers for diagnosis, plasma cells may occasionally be identified using CD138 immunostaining. Moreover, depending on the distribution of the lesions, it is also distinguished from UCD, which occurs only in a single lymph node, and MCD, which spreads to multiple regions. In principle, UCD corresponds to HV type, and MCD corresponds to PC type and M type. However, typical findings are not always obtained in the histopathological diagnosis of MCD, so careful judgment is required for each individual case, while carefully considering the available clinical information. The clinical symptoms of MCD include general malaise, fever, anemia, high value of CRP, hypergammaglobulinemia, and a variety of systemic symptoms and abnormalities upon testing. A diagnosis is made based on both the clinical symptoms and the histopathology of the enlarged lymph nodes (2). While clinical symptoms such as general malaise and fever were not observed in our case, low Hb and Alb values and a high gamma-globulin fraction were observed upon blood testing. In addition, due to the fact that a CT scan confirmed the enlargement of lymph nodes across multiple regions and that the degree of plasma cell infiltration was histopathologically high, it was diagnosed as a PC type of MCD.
While the most common site of Castleman disease is the mediastinum, 15% of such cases occur in the head and neck, and it is also known to occur in the abdominal cavity and axilla. The differential diagnosis of Castleman disease occurring in the neck includes inflammatory cervical lymphadenitis, cervical lymph node metastasis of malignant tumors, and malignant lymphoma, as well as sarcoidosis and IgG4-related diseases. If head and neck cancer is present, then cervical lymph node metastasis should first be suspected. In our case, multiple abnormal FDG accumulations were systemically observed in addition to cervical lymph nodes upon PET/CT, suggesting at least some form of lymphoproliferative disorder. However, regarding the cervical lymph nodes, because the possibility of metastasis from tongue cancer could not be ruled out, FNA was performed. As far as we were able to find, English-language reported cases of Castleman disease occurring in conjunction with head and neck cancer are extremely rare, with only three known cases, including our own case (8,9) (Table I). The average patient age was 47.7 years, with two patients in their 30s. There were two males and one female, with the cancer site being the tongue in all three cases. Histopathologically, two cases were HV type, and one case was PC type. Regarding the site of lymphadenopathy, two cases occurred at a single site (mediastinum, submandibular region) and one case occurred at multiple sites. As noted earlier, both of the two non-self cases of UCD corresponded to HV type. Lymphadenopathy was also observed in the neck in two cases, including our own case. In one case, under a diagnosis of cT1N3aM0, hemi-glossectomy and bilateral neck dissection were performed. However, no lymph node metastasis was observed in the postoperative histopathological diagnosis, so it may have been possible to treat the disease by partial resection alone. In our own case, only a partial glossectomy was performed based on the results of the preoperative FNA. To differentiate between metastatic lymph nodes from oral cancer and Castleman disease, cervical ultrasonography, CT, and MRI are first performed. However, as both conditions present with very similar imaging findings, a definitive diagnosis requires either FNA or a biopsy of the lymph node.
MCD is believed to be caused by the sustained production of interleukin-6 (IL-6) (10). For this reason, treatment is centered on IL-6 inhibitors, with siltuximab mainly used (11); however, tocilizumab (2), an anti-IL-6 receptor antibody, is the only approved treatment by the Japanese National Health Insurance System. In asymptomatic cases with only mild laboratory abnormalities, as in the present case, careful observation may be an appropriate management option. In moderate to severe cases, the concomitant use of steroids is recommended in addition to tocilizumab (12,13). With proper treatment, the prognosis is relatively good, with a 5-year overall survival rate of 100% and a 10-year overall survival rate of 90% or more in Japan (14). That said, obtaining a complete cure is difficult, with most patients not achieving permanent remission even via treatment with tocilizumab (15), so further therapeutic drug development and clinical trials are needed going forward.
While the relationship between Castleman disease and SCC has not been clarified, the involvement of IL-6 has been suggested (16). IL-6 is a cytokine involved in a variety of biological events, including immune reactions, hematopoiesis, and acute phase reactions, with the overproduction thereof thought to be involved in the development of chronic inflammatory diseases and cancers. Riedel et al (17) reported that they observed elevated serum IL-6 levels in head and neck SCCs, particularly in advanced cancers with lymph node metastases. In this case, the symptoms of Castleman disease were mild and asymptomatic, and since no active therapeutic intervention was undertaken and only observation was performed, the IL-6 levels were therefore not measured. Regarding the monitoring method, if Castleman disease and oral cancer coexist, as observed in this case, then it is necessary to confirm both lesions, with imaging examinations conducted once every 3 to 6 months considered to be appropriate. Although the course of MCD is generally slow, it is recommended to conduct systemic examinations such as PET/CT once a year. In addition, in conjunction with the Hematology Department, we should be prepared to respond quickly when symptoms appear.
We described a case of MCD that was incidentally detected during an evaluation of tongue cancer and reviewed the literature on this rare entity. Distinguishing between lymphadenopathy in Castleman disease and lymph node metastasis in oral cancer is difficult using just the clinical findings and images alone. In order to provide appropriate treatment, it is necessary to carry out a histopathological examination in cooperation with the relevant departments to make an appropriate diagnosis and stage classification.
Not applicable.
Funding: No funding was received.
The data generated in the present study may be requested from the corresponding author.
YY conceptualized the case report, performed the acquisition, analysis and interpretation of data and drafted the manuscript. YY, SS, MY, MN and KS were involved in the treatment and follow-up in this case. SA advised on patient treatment, analyzed patient data, critically revised the manuscript and provided valuable feedback, provided supervision, and approved the final manuscript for publication. YY and SA confirm the authenticity of all the raw data. All authors read and approved the final manuscript.
Not applicable.
The patient provided written informed consent for publication, authorizing the use of their imaging, pathological and clinical data for publication.
The authors declare that they have no competing interests.
|
Castleman B, Iverson L and Menendez VP: Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 9:822–830. 1956. View Article : Google Scholar : PubMed/NCBI | |
|
Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, et al: International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 129:1646–1657. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bartoli E, Massarelli G, Soggia G and Tanda F: Multicentric giant lymph node hyperplasia. A hyperimmune syndrome with a rapidly progressive course. Am J Clin Pathol. 73:423–426. 1980. View Article : Google Scholar | |
|
Gaba AR, Stein RS, Sweet DL and Variakojis D: Multicentric giant lymph node hyperplasia. Am J Clin Pathol. 69:86–90. 1978. View Article : Google Scholar | |
|
Frizzera G, Banks PM, Massarelli G and Rosai J: A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients. Am J Surg Pathol. 7:211–231. 1983. View Article : Google Scholar | |
|
Bonekamp D, Horton KM, Hruban RH and Fishman EK: Castleman disease: The great mimic. Radiographics. 31:1793–1807. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Keller AR, Hochholzer L and Castleman B: Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 29:670–683. 1972. View Article : Google Scholar : PubMed/NCBI | |
|
Deshmukh M, Bal M, Deshpande P and Jambhekar NA: Synchronous squamous cell carcinoma of tongue and unicentric cervical Castleman's disease clinically mimicking a stage IV disease: A rare association or coincidence? Head Neck Pathol. 5:180–183. 2011. View Article : Google Scholar | |
|
Pereira TC, Landreneau R, Nathan G and Sturgis CD: Pathologic quiz case. Large posterior mediastinal mass in a young woman. Pathologic diagnosis: Localized hyaline-vascular-type Castleman disease (angiofollicular lymphoid hyperplasia). Arch Pathol Lab Med. 125:964–967. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, et al: Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 106:2627–2632. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, et al: Siltuximab for multicentric Castleman's disease: A randomised, double-blind, placebo-controlled trial. Lancet Oncol. 15:966–974. 2014. View Article : Google Scholar | |
|
Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, Kishimoto T and Yoshizaki K: Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 95:56–61. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Dispenzieri A, Armitage JO, Loe MJ, Geyer SM, Allred J, Camoriano JK, Menke DM, Weisenburger DD, Ristow K, Dogan A and Habermann TM: The clinical spectrum of Castleman's disease. Am J Hematol. 87:997–1002. 2012. View Article : Google Scholar | |
|
Fujimoto S, Sakai T, Kawabata H, Kurose N, Yamada S, Takai K, Aoki S, Kuroda J, Ide M, Setoguchi K, et al: Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol. 94:975–983. 2019. View Article : Google Scholar | |
|
Carbone A, Borok M, Damania B, Gloghini A, Polizzotto MN, Jayanthan RK, Fajgenbaum DC and Bower M: Castleman disease. Nat Rev Dis Primers. 7:842021. View Article : Google Scholar : PubMed/NCBI | |
|
Matsumura N, Shiiki H, Saito N, Uramoto H, Hanatani M, Nonaka H and Nakamura S: Interleukin-6-producing thymic squamous cell carcinoma associated with Castleman's disease and nephrotic syndrome. Intern Med. 41:871–874. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Riedel F, Zaiss I, Herzog D, Götte K, Naim R and Hörmann K: Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res. 25:2761–2765. 2005.PubMed/NCBI |